Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractTo date, virulent bacteria remain the basis of most bacteria mediated cancer therapies. For clinical application attenuation is required. However, this might result in a drastically lowered therapeutic capacity. Herein we argue that the E. coli probiotic Symbioflor-2, with a history of safe application may constitute a viable tumor therapeutic candidate. We demonstrate that Symbioflor-2 displays a highly specific tumor targeting ability as determined in murine CT26 and RenCa tumor models. The excellent specificity was ascribed to reduced levels of adverse colonization. A high safety standard was demonstrated in WT and Rag1-/- mice. Thus, Symbioflor-2 may represent an ideal tumor targeting delivery system for therapeutic molecules. Moreover, Symbioflor-2 was capable of inducing CT26 tumor clearance as result of an adjuvant effect on tumor specific CD8+ T cells analogous to the Salmonella variant SL7207. However, lower therapeutic efficacy against RenCa tumors suggested a generally reduced therapeutic potency for probiotics. Interestingly, concurrent depletion of Gr-1+ or Ly6G+ cells installed therapeutic efficacy equal to SL7207, thus highlighting the role of innate effector cells in restraining the anti-tumor effects of Symbioflor-2. Collectively, our findings argue for a strategy of safe strain application and a more sustainable use of bacteria as a delivery system for therapeutic molecules.
CitationTherapy of solid tumors using probiotic Symbioflor-2: restraints and potential. 2016, 7 (16):22605-22 Oncotarget
AffiliationHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.
- Authors: Kocijancic D, Leschner S, Felgner S, Komoll RM, Frahm M, Pawar V, Weiss S
- Issue date: 2017 May 30
- Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
- Authors: Lehouritis P, Stanton M, McCarthy FO, Jeavons M, Tangney M
- Issue date: 2016 Jan 28
- Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.
- Authors: Kocijancic D, Felgner S, Schauer T, Frahm M, Heise U, Zimmermann K, Erhardt M, Weiss S
- Issue date: 2017 Jul 25
- Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules.
- Authors: Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, Buer J, Bruder D
- Issue date: 2005 Mar 1
- The B subunit of Escherichia coli enterotoxin helps control the in vivo growth of solid tumors expressing the Epstein-Barr virus latent membrane protein 2A.
- Authors: Ondondo B, Faulkner L, Williams NA, Morgan AJ, Morgan DJ
- Issue date: 2015 Mar